Literature DB >> 16049320

Establishment of a diabetic mouse model with progressive diabetic nephropathy.

Akari Inada1, Kojiro Nagai, Hidenori Arai, Jun-ichi Miyazaki, Keiko Nomura, Hiroshi Kanamori, Shinya Toyokuni, Yuichiro Yamada, Susan Bonner-Weir, Gordon C Weir, Atsushi Fukatsu, Yutaka Seino.   

Abstract

Although diabetic animal models exist, no single animal model develops renal changes identical to those seen in humans. Here we show that transgenic mice that overexpress inducible cAMP early repressor (ICER Igamma) in pancreatic beta cells are a good model to study the pathogenesis of diabetic nephropathy. Although ICER Igamma transgenic mice exhibit extremely high blood glucose levels throughout their lives, they survive long enough to develop diabetic nephropathy. Using this model we followed the progress of diabetic renal changes compared to those seen in humans. By 8 weeks of age, the glomerular filtration rate (GFR) was already increased, and glomerular hypertrophy was prominent. At 20 weeks, GFR reached its peak, and urine albumin excretion rate was elevated. Finally, at 40 weeks, diffuse glomerular sclerotic lesions were prominently accompanied by increased expression of collagen type IV and laminin and reduced expression of matrix metalloproteinase-2. Nodular lesions were absent, but glomerular basement membrane thickening was prominent. At this point, GFR declined and urinary albumin excretion rate increased, causing a nephrotic state with lower serum albumin and higher serum total cholesterol. Thus, similar to human diabetic nephropathy, ICER Igamma transgenic mice exhibit a stable and progressive phenotype of diabetic kidney disease due solely to chronic hyperglycemia without other modulating factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049320      PMCID: PMC1603579          DOI: 10.1016/s0002-9440(10)62978-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription.

Authors:  N S Foulkes; E Borrelli; P Sassone-Corsi
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

Review 2.  Animal models of spontaneous diabetic kidney disease.

Authors:  M T Velasquez; P L Kimmel; O E Michaelis
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

3.  Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia.

Authors:  T Doi; M Hattori; L Y Agodoa; T Sato; H Yoshida; L J Striker; G E Striker
Journal:  Lab Invest       Date:  1990-08       Impact factor: 5.662

Review 4.  The NOD mouse as a model of type I diabetes.

Authors:  Y Tochino
Journal:  Crit Rev Immunol       Date:  1987       Impact factor: 2.214

Review 5.  Epidemiologic approach to the etiology of type I diabetes mellitus and its complications.

Authors:  A S Krolewski; J H Warram; L I Rand; C R Kahn
Journal:  N Engl J Med       Date:  1987-11-26       Impact factor: 91.245

6.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.

Authors:  Y Yamamoto; I Kato; T Doi; H Yonekura; S Ohashi; M Takeuchi; T Watanabe; S Yamagishi; S Sakurai; S Takasawa; H Okamoto; H Yamamoto
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

7.  Animal model of diabetic nephropathy.

Authors:  T Yokozawa; T Nakagawa; K Wakaki; F Koizumi
Journal:  Exp Toxicol Pathol       Date:  2001-10

8.  Induced ICER Igamma down-regulates cyclin A expression and cell proliferation in insulin-producing beta cells.

Authors:  Akari Inada; Gordon C Weir; Susan Bonner-Weir
Journal:  Biochem Biophys Res Commun       Date:  2005-04-15       Impact factor: 3.575

9.  Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy.

Authors:  R Zatz; T W Meyer; H G Rennke; B M Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  The Os/+ mouse: a genetic animal model of reduced renal mass.

Authors:  R K Zalups
Journal:  Am J Physiol       Date:  1993-01
View more
  13 in total

Review 1.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 2.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

3.  The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats.

Authors:  Sang Hoon Kim; Young Woo Jang; Patrick Hwang; Hyun Jung Kim; Gi Yeon Han; Chan Wha Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

4.  Early protective effect of mitofusion 2 overexpression in STZ-induced diabetic rat kidney.

Authors:  Wan Xin Tang; Wei Hua Wu; Xiao Xi Zeng; Hong Bo; Song Min Huang
Journal:  Endocrine       Date:  2011-11-18       Impact factor: 3.633

5.  Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c.

Authors:  Byoung Geun Han; Chuan-Ming Hao; Elena E Tchekneva; Ying-Ying Wang; Chieh Allen Lee; Benyamin Ebrahim; Raymond C Harris; Timothy S Kern; David H Wasserman; Matthew D Breyer; Zhonghua Qi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

6.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

7.  Adjusting the 17β-Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy.

Authors:  Akari Inada; Oogi Inada; Nobuharu L Fujii; Seiho Nagafuchi; Hitoshi Katsuta; Yohichi Yasunami; Takeshi Matsubara; Hidenori Arai; Atsushi Fukatsu; Yo-Ichi Nabeshima
Journal:  J Am Soc Nephrol       Date:  2016-03-03       Impact factor: 10.121

Review 8.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

9.  Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.

Authors:  Chunbo Zou; Rujuan Xie; Yushi Bao; Xiaogang Liu; Manshu Sui; Suhong M; Shuang Li; Huiqing Yin
Journal:  Endocrine       Date:  2013-03-07       Impact factor: 3.633

10.  Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.

Authors:  Masako Furukawa; Tomohito Gohda; Shinji Hagiwara; Mitsuo Tanimoto; Satoshi Horikoshi; Kazuhiko Funabiki; Yasuhiko Tomino
Journal:  Int J Nephrol       Date:  2013-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.